大剂量吉西他滨、白消安和美法仑用于复发或难治性骨髓瘤自体干细胞移植:一项2期试验及与美法仑的配对比较
在MD安德森癌症中心开展的2期试验纳入74例复发或难治性骨髓瘤患者,接受吉西他滨、白消安和美法仑方案后,可测量疾病患者中24.6%达到严格完全缓解,高于同期对照组的12.6%(p=0.040);配对对照分析显示该方案无进展生存和总生存均优于美法仑,但需前瞻性随机试验证实。
要点
- 吉西他滨、白消安和美法仑方案在可测量疾病患者中严格完全缓解率为24.6%,对照组为12.6%(p=0.040)。
- 配对对照中该方案中位无进展生存15.1个月 vs 9.3个月(HR 0.55),中位总生存37.5个月 vs 23.0个月(HR 0.60)。
- 该方案3级或以上不良事件包括3级黏膜炎12例、3级皮炎5例、3级转氨酶升高7例、3级腹泻2例,治疗相关死亡3例。
核心结论
- 吉西他滨、白消安和美法仑是复发或难治性骨髓瘤自体干细胞移植中相对安全且有效的方案。
- 接受该方案的患者结局优于同期接受美法仑的配对队列,但需前瞻性随机试验证实。
研究设计与样本
- 在德克萨斯大学MD安德森癌症中心开展的2期试验,纳入74例原发难治或复发骨髓瘤患者。
- 患者此前接受过硼替佐米、免疫调节药物或两者,或正在接受挽救性自体干细胞移植。
- 吉西他滨1875 mg/m2静脉输注3小时,连续2天;随后白消安目标曲线下面积4000 μmol/L每min每天,连续4天;美法仑60 mg/m2每天,连续2天。
- 主要终点为可测量疾病患者中达到严格完全缓解的比例(按国际骨髓瘤工作组标准)。
- 与同期符合条件但拒绝参与或无保险覆盖而接受美法仑200 mg/m2静脉输注30分钟1天的184例患者进行回顾性配对比较,按1-2:1比例匹配性别、年龄、疾病状态、对蛋白酶体抑制剂和免疫调节酰亚胺药物双重难治、诊断至移植时间及细胞遗传学风险。
主要发现
- 74例患者中位年龄58岁(IQR 51-62),中位既往治疗线数2线(2-5),38例高危细胞遗传学,17例对所有既往治疗无反应,32例接受挽救性自体干细胞移植。
- 可测量疾病患者中,吉西他滨、白消安和美法仑组65例中16例(24.6%,95%CI 14.2-35.0)达到严格完全缓解,同期对照组174例中22例(12.6%,95%CI 10.1-15.1)达到严格完全缓解(p=0.040)。
- 吉西他滨、白消安和美法仑组中位随访36个月(IQR 30-46),配对对照组(n=111)中位随访34个月(IQR 25-53)。
- 吉西他滨、白消安和美法仑组中位无进展生存15.1个月(95%CI 8.7-22.1) vs 配对对照组9.3个月(95%CI 8.0-10.7),进展或死亡风险显著降低(HR 0.55,95%CI 0.38-0.81,log-rank p=0.030)。
- 吉西他滨、白消安和美法仑组中位总生存37.5个月(95%CI 26-未达到) vs 配对对照组23.0个月(95%CI 16.6-30.5),死亡风险降低(HR 0.60,95%CI 0.34-0.84,log-rank p=0.0092)。
关键数值与推荐
- 可测量疾病患者中严格完全缓解:吉西他滨、白消安和美法仑组24.6%(16/65,95%CI 14.2-35.0) vs 同期对照组12.6%(22/174,95%CI 10.1-15.1),p=0.040。
- 配对对照中位无进展生存:吉西他滨、白消安和美法仑组15.1个月(95%CI 8.7-22.1) vs 对照组9.3个月(95%CI 8.0-10.7),HR 0.55(95%CI 0.38-0.81),log-rank p=0.030。
- 配对对照中位总生存:吉西他滨、白消安和美法仑组37.5个月(95%CI 26-未达到) vs 对照组23.0个月(95%CI 16.6-30.5),HR 0.60(95%CI 0.34-0.84),log-rank p=0.0092。
局限性
- 与美法仑的配对比较为回顾性分析。
- 作者指出该方案的优势需在前瞻性随机试验中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose melphalan is of little benefit as a regimen for patients with relapsed or refractory myeloma undergoing an autologous stem-cell transplant (ASCT). The poor performance of single-agent melphalan in this setting prompted us to study a new high-dose combination of infused gemcitabine, busulfan, and melphalan. METHODS: We did a phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). We enrolled patients with primary refractory or relapsed myeloma who had received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a salvage ASCT. Gemcitabine was infused at 1875 mg/m2 for 3 h for 2 days, followed by busulfan (target area under the curve 4000 μmol/L per min per day for 4 days) and melphalan (60 mg/m2 per day for 2 days). The primary endpoint of this trial was to establish the proportion of patients with measurable disease at ASCT receiving gemcitabine, busulfan, and melphalan who achieved stringent complete remission in accordance with the International Myeloma Working Group criteria. We then retrospectively compared the patients in this study with all other concurrent patients at the MD Anderson Cancer Center who were eligible for this trial but declined to participate or had no financial coverage for ASCT in a clinical trial and instead received melphalan at 200 mg/m2 intravenously over 30 min on 1 day, followed by ASCT (control group). To compare survival outcomes, we used a statistical algorithm to select a subset of patients from this control cohort who were matched in a 1-2:1 ratio with the patients in the gemcitabine, busulfan, and melphalan group by sex, age, disease status, refractory to both proteasome inhibitors and immunomodulatory imide drugs, time from diagnosis to ASCT, and cytogenetic risk. All analyses were per protocol. This is the final analysis of the clinical trial, which is registered at ClinicalTrials.gov, number NCT01237951. FINDINGS: Between Nov 30, 2010, and Dec 11, 2013, we enrolled 74 patients into the gemcitabine, busulfan, and melphalan trial. In these patients, median age was 58 years (IQR 51-62), median number of previous lines of therapy was two (2-5), 38 patients had high-risk cytogenetics, 17 were unresponsive to all previous treatments, and 32 were receiving a salvage ASCT. We identified 184 patients for the concurrent control cohort. The study patients and the concurrent controls received similar post-ASCT maintenance. Among patients with measurable disease at ASCT, 16 of 65 patients (24·6%, 95% CI 14·2-35·0) in the gemcitabine, busulfan, and melphalan group had stringent complete remission compared with 22 of 174 patients (12·6%, 10·1-15·1) in the concurrent control group (p=0·040). Median follow-up time was 36 months (IQR 30-46) in the patients receiving gemcitabine, busulfan, and melphalan and 34 months (25-53) in the matched control subset (n=111). With respect to the secondary survival endpoints, the gemcitabine, busulfan, and melphalan cohort had significantly longer median progression-free survival than the matched control cohort (15·1 months [95% CI 8·7-22·1] vs 9·3 months [8·0-10·7]) with a significantly reduced risk of progression or death (HR 0·55, 95% CI 0·38-0·81, log-rank p=0·030), as well as significantly longer median overall survival (37·5 months [26-not reached] vs 23·0 months [16·6-30·5]) and a lower risk of death (HR 0·60, 0·34-0·84, log-rank p=0·0092). For only the patients treated with gemcitabine, busulfan, and melphalan, grade 3 or worse adverse events included grade 3 mucositis (12 patients), grade 3 dermatitis (five patients), grade 3 aminotransferase elevation (seven patients), grade 3 diarrhoea (two patients), and three treatment-related deaths. One death was cardiac sudden death and two were due to sepsis. INTERPRETATION: Gemcitabine, busulfan, and melphalan is a comparatively safe and active regimen for ASCT in patients with refractory or relapsed myeloma. Better outcomes were achieved in patients who received this regimen than in a concurrent matched cohort receiving melphalan, although this will need to be confirmed in a prospective, randomised trial. FUNDING: Otsuka Pharmaceutical Development & Commercialization and US National Cancer Institute.
引用
- Nieto Y, Valdez BC, Pingali SR, et al. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017. PMID: 28522110. doi:10.1016/S2352-3026(17)30080-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。